Nektar Therapeutics reported $0 in Loan Capital for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Loan Capital Change
Agios Pharmaceuticals AGIO:US USD 1.06M 0
ALKERMES ALKS:US USD 290.9M 633K
Amgen AMGN:US USD 37.35B 193M
Astrazeneca AZN:US USD 23.68B 3.47B
Baxter International BAX:US USD 16.15B 125M
Biogen BIIB:US USD 6.28B 1.8M
Esperion Therapeutics ESPR:US USD 259.49M 407K
GlaxoSmithKline GSK:LN GBP 17.04B 2.29B
Halozyme Therapeutics HALO:US USD 1.49B 344.03M
IONIS PHARMACEUT IONS:US USD 1.25B 1.1M
Ironwood Pharmaceuticals IRWD:US USD 395.85M 399K
Karyopharm Therapeutics KPTI:US USD 302.89M 201K
Novartis NOVN:VX USD 21.24B 2.55B
Roche Holding ROG:VX 22.37B 6.29B
Sarepta Therapeutics SRPT:US USD 1.54B 441.9M
Takeda 4502:JP JPY 3.91T 253.53B
Teva Pharmaceutical TEVA:IT USD 18.5B 1.87B
YTE INCY:US USD 30.48M 681K